title: miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression.
abstract: Non-small-cell lung cancer (NSCLC) is one of the most leading causes of cancer-related deaths worldwide. Paclitaxel based combination therapies have long been used as a standard treatment in aggressive NSCLCs. But paclitaxel resistance has emerged as a major clinical problem in combating non-small-cell lung cancer and autophagy is one of the important mechanisms involved in this phenomenon. In this study, we used microRNA (miRNA) arrays to screen differentially expressed miRNAs between paclitaxel sensitive lung cancer cells A549 and its paclitaxel-resistant cell variant (A549-T24). We identified miR-17-5p was one of most significantly downregulated miRNAs in paclitaxel-resistant lung cancer cells compared to paclitaxel sensitive parental cells. We found that overexpression of miR-17-5p sensitized paclitaxel resistant lung cancer cells to paclitaxel induced apoptotic cell death. Moreover, in this report we demonstrated that miR-17-5p directly binds to the 3'-UTR of beclin 1 gene, one of the most important autophagy modulator. Overexpression of miR-17-5p into paclitaxel resistant lung cancer cells reduced beclin1 expression and a concordant decease in cellular autophagy. We also observed similar results in another paclitaxel resistant lung adenosquamous carcinoma cells (H596-TxR). Our results indicated that paclitaxel resistance of lung cancer is associated with downregulation of miR-17-5p expression which might cause upregulation of BECN1 expression.
authors.affiliation: Department of Biotechnology and Dr. B.C. Guha Centre for Genetic Engineering and Biotechnology, University of Calcutta, Kolkata, WB, India.
authors.forename: Abhisek
authors.initials: A
authors.lastname: Chatterjee
authors.affiliation: Department of Biotechnology and Dr. B.C. Guha Centre for Genetic Engineering and Biotechnology, University of Calcutta, Kolkata, WB, India.
authors.forename: Dhrubajyoti
authors.initials: D
authors.lastname: Chattopadhyay
authors.affiliation: Department of Biotechnology and Dr. B.C. Guha Centre for Genetic Engineering and Biotechnology, University of Calcutta, Kolkata, WB, India.
authors.forename: Gopal
authors.initials: G
authors.lastname: Chakrabarti
mesh_terms: D020413:3' Untranslated Regions; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D051017:Apoptosis Regulatory Proteins / Q000737:chemistry / Q000235:genetics*; D001343:Autophagy / Q000187:drug effects / Q000235:genetics; D001483:Base Sequence; D000071186:Beclin-1; D001665:Binding Sites; D045744:Cell Line, Tumor; D016000:Cluster Analysis; D045304:Cytochromes c / Q000378:metabolism; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects / Q000235:genetics; D008565:Membrane Proteins / Q000737:chemistry / Q000235:genetics*; D035683:MicroRNAs / Q000737:chemistry / Q000235:genetics*; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D017239:Paclitaxel / Q000494:pharmacology*; D012333:RNA, Messenger / Q000235:genetics; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D020413:3' Untranslated Regions; D000972:Antineoplastic Agents, Phytogenic; D051017:Apoptosis Regulatory Proteins; C491997:BECN1 protein, human; D000071186:Beclin-1; C524941:MIRN17 microRNA, human; D008565:Membrane Proteins; D035683:MicroRNAs; D012333:RNA, Messenger; D017382:Reactive Oxygen Species; D045304:Cytochromes c; D017239:Paclitaxel
references.citation: Curr Genomics. 2010 Nov;11(7):537-61
references.pmid: 21532838
references.citation: Cancer Lett. 2011 Aug 28;307(2):141-8
references.pmid: 21511395
references.citation: Science. 2007 Mar 16;315(5818):1576-9
references.pmid: 17322030
references.citation: BMC Cancer. 2009 Jun 30;9:215
references.pmid: 19566920
references.citation: Nature. 1999 Jun 3;399(6735):483-7
references.pmid: 10365962
references.citation: Nat Rev Cancer. 2006 Apr;6(4):259-69
references.pmid: 16557279
references.citation: Obstet Gynecol Sci. 2013 Mar;56(2):84-92
references.pmid: 24327986
references.citation: J Biol Chem. 2010 Jun 18;285(25):19076-84
references.pmid: 20406806
references.citation: Bull Cancer. 2005 Feb;92(2):E25-30
references.pmid: 15749640
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Free Radic Biol Med. 2001 Aug 15;31(4):548-58
references.pmid: 11498288
references.citation: J Biol Chem. 2010 Jul 9;285(28):21496-507
references.pmid: 20460378
references.citation: PLoS One. 2013;8(2):e56679
references.pmid: 23441212
references.citation: Cell. 2009 Feb 20;136(4):642-55
references.pmid: 19239886
references.citation: Cancer Biol Ther. 2013 Jul;14(7):574-86
references.pmid: 23792642
references.citation: Oncogene. 2011 Oct 27;30(43):4386-98
references.pmid: 21552288
references.citation: Cancer Cell. 2003 Jan;3(1):51-62
references.pmid: 12559175
references.citation: Nature. 2005 Dec 1;438(7068):671-4
references.pmid: 16319892
references.citation: Clin Cancer Res. 2011 Feb 15;17(4):654-66
references.pmid: 21325294
references.citation: Breast Cancer Res Treat. 2006 Mar;96(1):17-39
references.pmid: 16322897
references.citation: Curr Protoc Immunol. 2001 May;Appendix 3:Appendix 3B
references.pmid: 18432654
references.citation: Biochem Biophys Res Commun. 2007 Nov 23;363(3):542-6
references.pmid: 17889832
references.citation: Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2503-8
references.pmid: 20133800
references.citation: Methods Mol Biol. 2010;594:57-72
references.pmid: 20072909
references.citation: Clin Cancer Res. 2005 Jan 1;11(1):298-305
references.pmid: 15671559
references.citation: Cancer Lett. 2009 Mar 8;275(1):54-60
references.pmid: 19010591
references.citation: Cell Death Dis. 2012 Jan 26;3:e260
references.pmid: 22278287
references.citation: Mol Cancer Ther. 2008 May;7(5):1150-5
references.pmid: 18445659
references.citation: J Clin Invest. 1997 Sep 1;100(5):1282-93
references.pmid: 9276747
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: Cell Death Differ. 2002 Jun;9(6):636-42
references.pmid: 12032672
references.citation: J Cell Sci. 2001 Oct;114(Pt 20):3619-29
references.pmid: 11707514
references.citation: N Engl J Med. 1995 Apr 13;332(15):1004-14
references.pmid: 7885406
references.citation: Nature. 2004 Sep 16;431(7006):350-5
references.pmid: 15372042
references.citation: Mayo Clin Proc. 2008 May;83(5):584-94
references.pmid: 18452692
references.citation: Curr Opin Investig Drugs. 2009 Dec;10(12):1269-79
references.pmid: 19943199
references.citation: Proc Natl Acad Sci U S A. 1988 Jun;85(11):3762-6
references.pmid: 2897689
references.citation: Biochim Biophys Acta. 2008 Apr;1785(2):96-132
references.pmid: 18068131
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14681-6
references.pmid: 9843949
references.citation: Cancer Res. 1985 Aug;45(8):3856-63
references.pmid: 2861892
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Mol Cancer Ther. 2009 May;8(5):1055-66
references.pmid: 19435871
references.citation: Biochemistry. 2009 Jul 28;48(29):6963-74
references.pmid: 19527023
references.citation: Cancer Res. 2004 Apr 1;64(7):2502-8
references.pmid: 15059905
references.citation: Autophagy. 2012 Jul 1;8(7):1032-44
references.pmid: 22562073